Why IDH and 1p/19q are two questions, not one
Patients often treat 'IDH and 1p/19q' as a single label. They are not. IDH is a gene result: the report should say whether an IDH mutation was detected, which IDH gene was tested, and what method was used. The 1p/19q result is a chromosome finding: the report should say whether codeletion of chromosome arms 1p and 19q was detected, and how that was assessed.
The reason the distinction matters is practical. A report that says only 'glioma' or 'oligodendroglial features' leaves the treating team to interpret an incomplete picture. A report that states both results, with the method and the specimen, gives the neurosurgery and oncology teams a clearer starting point for discussing tumour type, grade and site alongside your circumstances.
Assessment of an adult central nervous system tumour considers tumour type, site and grade together with the patient's circumstances, and treatment decisions are individual. That is the frame to keep in mind: the molecular report informs the discussion, but it does not by itself decide what any particular team will recommend for you.
What a complete molecular report should state
When you look at your pathology report, you are checking whether the document answers specific questions. If any of these are missing, that is a gap to raise with the team holding your records, not a conclusion you should draw yourself.
First, the specimen. Was the tissue from a biopsy or a resection, and which part of the tumour did it come from? A small sample and a larger resection can give different amounts of information, and the report should identify what was tested.
Second, the IDH result. The report should name the IDH gene tested, state whether a mutation was detected, and describe the method. A statement such as 'IDH wild-type' or 'IDH mutant' without the gene and method is harder for a receiving team to interpret.
Third, the 1p/19q result. The report should state whether codeletion was detected and name the technique used to assess it. A phrase like '1p/19q status pending' or 'not assessable' is different from a negative result, and the difference matters when a team is reviewing your file.
Fourth, the grade and the integrated diagnosis. The report should give the tumour grade and the diagnostic line the pathologist reached, not only a descriptive comment. If the report uses older terminology, ask whether an addendum or a re-review is appropriate.
Fifth, the date and the laboratory. A receiving team needs to know when the testing was done and where, because that affects whether the result can be accepted as it stands or whether the slides and blocks need to be requested.
Why a missing result changes the China conversation
If your report does not clearly state IDH and 1p/19q, a Chinese neurosurgery team reviewing your file may not be able to confirm the tumour category from the documents alone. That does not mean care is impossible. It means the first useful step is often to clarify what is missing and whether the original slides, blocks or tissue can be requested for review.
This is where patients sometimes lose time. They send a summary that says 'oligodendroglioma' without the supporting molecular detail, then wait for a response that cannot be given because the key information is absent. A clearer file does not guarantee acceptance or a particular plan, but it gives the team something concrete to assess.
It also affects how you describe your situation. If you have an earlier treatment history, the receiving team will want to know what was done, when, and what the response was. The molecular report and the treatment history are read together, because sequencing questions depend on both.
One practical point: do not assume that a report from one laboratory will be accepted without question by another. Ask the receiving team whether they want the original slides and blocks sent, or whether a report alone is sufficient for their review. That is a question for them, not something you should decide in advance.
How to prepare your records before you enquire
You do not need to send a complete archive at first contact. A short summary is enough to start, and the team can tell you what else is needed. What helps most is a clear, organised set of documents that a clinician can read quickly.
Prepare a one-page summary that lists your diagnosis as stated, the date of diagnosis, the tumour site and grade if known, and the treatments you have already had with dates. Then attach the pathology report, the molecular report if separate, and the most recent imaging report.
If your IDH or 1p/19q result is unclear or missing, say so directly in your summary. A statement such as 'molecular report does not state 1p/19q status; original slides available on request' is more useful than leaving the gap for the team to discover.
Keep the documents in the language they were issued in, and note whether an English translation exists. If translation is needed, ask the receiving team what they require before you pay for anything.
Finally, write down your main question. Are you asking whether the diagnosis is correct, whether further treatment is possible, or how a treatment plan might be sequenced? A specific question gets a more specific response than a general request for an opinion.
Questions to ask the treating team about your report
When you speak with a neurosurgery or neuro-oncology team, the useful questions are about your file, not about general disease information. Ask whether they have reviewed the molecular report and whether they consider the IDH and 1p/19q results sufficient to confirm the tumour category.
Ask whether they want the original slides and blocks, and whether a pathology re-review is needed before they can discuss treatment options. Ask how the earlier treatment history affects their view of sequencing, and what records they still need.
Ask what the next step is if a result is missing or not assessable, and who would arrange any further testing. Ask whether the plan they describe is based on the records you have provided or whether it is provisional pending more information.
These are questions for the clinical team. They are not decisions you should make from a report alone, and no article can tell you what your own team will recommend.
Where ChinaSpecialistCare fits, and what to do next
ChinaSpecialistCare provides information and non-clinical coordination for international patients considering care in China. We can help you organise your records, identify what is missing from your file, and request a specialist appointment or a records-based opinion from a relevant hospital team. We do not diagnose, and we do not decide suitability or treatment.
If your file is incomplete, the free initial case review is a reasonable starting point. Our team checks the available diagnosis, records and your main question, identifies missing information and suggests the relevant next step. This is not a diagnosis or a promise of acceptance, and an initial enquiry does not require buying a proxy consultation.
For a confirmed or suspected glioma, the related reference page is Glioma Surgery, listed under the section links. That page describes the procedure context; it does not replace a clinical assessment of your own records.
A practical next step: gather your pathology report, molecular report and treatment summary, note whether IDH and 1p/19q are clearly stated, and send a short summary through the enquiry form. Ask specifically what records the receiving team needs and whether they want the original slides. Hospital acceptance and any treatment decision remain with the treating hospital and licensed clinicians.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.